Topic resource collection
Approved comparison material connected to this topic.
4 resourcesRead both sides
| Attribute | Research-Grade VIP Peptide | FDA-Approved Drug ||—|—|—|—|—|—|| Regulatory Pathway | Manufactured under GMP or ISO 9001; no FDA premarket approval required | Requires Phase I–III clinical trials, New Drug Application…
Legal Basis 21 CFR 312.2(b)(1) investigational use exemption Section 503A/503B patient-specific compounding None. Requires FDA drug approval Research peptides are federally protected; clinical requires prescription; bulk products…
Research-grade LIPO-C purchased for laboratory studies operates under 21 CFR 312.2(b)(1), the investigational use exemption. This regulation permits manufacture and interstate shipment of unapproved drug substances when intended …
GLP-1 Compounding (503A) Allowed during shortage Prohibited after April 2026 delisting Immediate cessation required No compounding of semaglutide/tirzepatide under 503A authority Complete market exit for traditional pharmacies. O…